肝细胞癌靶向和免疫治疗中疗效预测相关的生物学标志物研究进展

摘要/Abstract

摘要： 肝细胞癌（hepatocellular carcinoma ,HCC）是我国最常见的肝脏恶性肿瘤,严重威胁我国人民的生命和健康。目前,晚期HCC的治疗是以靶向和免疫治疗为主的系统性治疗,如何选择多靶点的抑制剂和合适的免疫治疗方案是当前研究的一大热点。随着各种基因测序技术的不断发展,探索靶向治疗和免疫治疗的生物学标志物,可精准地选择获益人群,预测药物疗效和疾病预后。本文将就HCC靶向和免疫治疗中疗效预测相关的生物学标志物研究进展进行综述。

关键词: 肝细胞癌, 分子靶向治疗, 免疫治疗, 生物学标志物

Abstract: Hepatocellular carcinoma (HCC) is the most common malignant liver tumor in China, which is seriously threating the life and health of our people. At present, molecular targeted therapy and immunotherapy are the mainly systematic treatment for advanced HCC. How to choose multi-targeted inhibitor and appropriate immunotherapy has become a research hotspot nowadays. With the continuous development of various sequencing technology, exploring the biomarkers of molecular targeted therapy and immunotherapy can precise select the beneficial population as well as predict drugs efficacy and disease prognosis. In this paper, we will review the advances of biomarker for efficacy prediction in targeted therapy and immunotherapy of hepatocellular carcinoma.

Key words: Hepatic carcinoma, Molecular targeted therapy, Immunotherapy, Biomarkers

何健, 陈晓明. 肝细胞癌靶向和免疫治疗中疗效预测相关的生物学标志物研究进展[J]. 肝癌电子杂志, 2020, 7(3): 39-42.

He Jian, Chen Xiaoming. Advances of biomarker for efficacy prediction in targeted therapy and immunotherapy of hepatocellular carcinoma[J]. Electronic Journal of Liver Tumor, 2020, 7(3): 39-42.

参考文献

[1] BRAY F, FERLAY J, SOERJOMATARAM I, et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence andmortality world wide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424.
[2] CHEN WQ, SUN K, ZHENG RS, et al.Cancer incidence and mortality in China, 2014[J]. Chin J Cancer Res, 2018, 30(1):1-12.
[3] BRUIX J,SHERMAN M,LLOVET JM,et al.Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver[J]. J Hepatol, 2001, 35(3):421-430.
[4] LLOVET JM, RICCI S, MAZZAFERRO V,et al.Sorafenib in advanced hepatocellular carcinoma[J]. N Engl J Med,2008,359(4):378-390.
[5] KUDO M,FINN RS,QIN S, et al.Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma:a randomized phase 3 non-inferiority trial[J]. Lancet,2018, 391(10126):1163-1173.
[6] FINN RS, QIN S, IKEDA M,et al.Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma[J]. N Engl J Med, 2020, 382(20):1894-1905.
[7] VOGEL A, CERVANTES A, CHAU I, et al.Hepatocellular carcinoma:ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2019, 30(5):871-873.
[8] BENSON AB, D'ANGELICA MI, ABBOTT DE, et al. Guidelines Insights: Hepatobiliary Cancers, Version 2. 2019[J]. J Natl Compr Canc Netw, 2019, 17(4):302-310.
[9] Horwitz E, Stein I, Andreozzi M, et al.Human and Mouse VEGFA-Amplified Hepatocellular Carcinomas Are Highly Sensitive to Sorafenib Treatment[J]. Cancer Discovery, 2014, 4(6):730-743.
[10] HORWITZ E, STEIN I, ANDREOZZI M, et al.Human and Mouse VEGFA-Amplified Hepatocellular Carcinomas Are Highly Sensitive to Sorafenib Treatment[J]. Cancer Discovery, 2014, 4(6):730-743.
[11] ARAO T, UESHIMA K, MATSUMOTO K, et al.FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma[J]. Hepatology, 2013, 57(4):1407-15.
[12] KAIBORI M, SAKAI K, ISHIZAKI M, et al.Increased FGF19 copy number is frequently detected in hepatocellular carcinoma with a complete response after sorafenib treatment[J]. Oncotarget, 2016, 7(31):49091-49098.
[13] TEUFEL M, SEIDEL H, KOCHERT K, et al.Biomarkers Associated With Response to Regorafenib in Patients With Hepatocellular Carcinoma[J]. Gastroenterology, 2019, 156(6):1731-1741.
[14] ZHU AX, KUDO M, ASSENAT E, et al.Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib:the EVOLVE-1 randomized clinical trial[J]. JAMA, 2014, 312(1):57-67.
[15] HUYNH H, HAO HX, CHAN SL, et al.Loss of tuberous sclerosis complex 2 (TSC2) is frequent in hepatocellular carcinoma and predicts response to mTORC1 inhibitor everolimus[J]. Mol Cancer Ther, 2015, 14(5):1224-35.
[16] RIMASSA L, ASSENAT E, PECK-RADOSAVLJEVIC M, et al.Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC):a final analysis of a phase 3, randomised, placebo-controlled study[J]. Lancet Oncology, 2018, 19(5):682-693.
[17] KIM RD, SARKER D, MEYER T, et al.First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma[J]. Cancer Discov, 2019, 9(12):1696-1707.
[18] ZHENG CH, ZHENG LT, YOO JK, et al.Landscape of Infiltrating T Cells in Liver Cancer Revealed by Single-Cell Sequencing[J]. Cell, 2017, 169(7):1342-1356.
[19] O’DONNELL JS, TENG MWL, SMYTH MJ. Cancer immunoediting and resistance to T cell-based immunotherapy[J]. Nat Rev Clin Oncol, 2019, 16(3):151-167.
[20] KUDO M, MATILLA A, SANTORO A, et al.Checkmate-040:nivolumab(NIVO) in patients with advanced hepatocellular carcinoma(aHCC) and Child-Pugh B(CPB) status. J Clin Oncol, 2019, 37(Suppl 4):327.
[21] SANGRO B, PARK JW, CRUZ CMD, et al.A randomized, multicenter, phase 3 study of nivolumab vs sorafenib as firstline treatment in patients(pts) with advanced hepatocellular carcinoma(HCC):CheckMate-459[J]. J Clin Oncol, 2016, 34(Suppl 15):4147.
[22] ZHU AX, FINN RS, EDELINE J, et al.Pembrolizumab in patients with advanced hepatocellular carcinoma previous treated with sorafenib (KEYNOTE-224):a non-randomised, open-label phase 2 trial[J]. Lancet Oncol, 2018, 19(7):940-952.
[23] LEMERY S, KEEGAN P, PAZDUR R.First FDA Approval Agnostic of Cancer Site-When a Biomarker Defines the Indication[J]. N Engl J Med, 2017, 377(15):1409-1412.
[24] TOMOKAZU K, YUWA A, MASAMI Y, et al.Incidence of microsatellite instability-high hepatocellular carcinoma among Japanese patients and response to pembrolizumab[J]. Hepatol Res,2020, 50(7):885-888.
[25] GOODMAN AM, KATO S, BAZHENOVA L, et al.Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers[J]. Mol Cancer Ther, 2017, 16(11):2598-2608.
[26] MARABLLE A, FAKIH M, LOPEZ J, et al.Association of Tumor Mutational Burden with Outcomes in Patients with Select Advanced Solid Tumors Treated with Pembrolizumab in KEYNOTE-158[J]. Ann Oncol, 2019, 30(Suppl 5):475-532.
[27] SHAO YY, LIU TH, HSU C, et al.Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma[J]. Liver international, 2019, 39(11):2184-2189.
[28] ZHU AX, KANG YK, YEN CJ, et al.Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2):a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2019, 20(2):282-296.